Breast cancer is increasingly prevalent in older adults and is a substantial part of routine
oncology practice. However, management of breast cancer in this population is challenging …

This work provides a systematic review of the literature from January 2003 to April 2014
pertaining to the incidence, pathophysiology, diagnosis, and treatment of osteonecrosis of …

Strategies for management of patients with, or at risk for, medication-related osteonecrosis of
the jaw (MRONJ) were set forth in the American Association of Oral and Maxillofacial …

Background Medication‐related osteonecrosis of the jaw (MRONJ) is a severe adverse
reaction experienced by some individuals to certain medicines commonly used in the …

Background Bone is the most common site of metastatic disease associated with breast
cancer (BC). Bisphosphonates inhibit osteoclast‐mediated bone resorption, and novel …

Context Antiresorptive therapy significantly reduces fracture risk in patients with benign bone
disease and skeletal-related events (SREs) in patients with bone metastases (BM) …

Background Medication-related osteonecrosis of the jaw (MRONJ) is a rare, but serious
adverse effect of certain drugs, of which bisphosphonates are the most widely known. This …

Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse drug reaction,
consisting of progressive bone destruction in the maxillofacial region of patients. ONJ can be …

Long-term bisphosphonate therapy is associated with increased risk of osteonecrosis of the
jaw (ONJ). In a retrospective analysis, a 16% ONJ incidence was reported in patients …

This article has 2 primary goals: to provide the best current frequency estimate of medication-
related osteonecrosis of the jaws (MRONJ) and to identify factors associated with the risk of …